ArticleInternational cancer conference journal2020
Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
Article in International cancer conference journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Immunotherapy in Bellini Duct Carcinoma: A Systematic Review.Oncology research · 2026Pooled it
- Rare renal tumor: a case report of collecting duct carcinoma and literature review.Frontiers in oncology · 2026Article
- Good response with nivolumab and cabozantinib combination therapy in patients with metastatic collecting duct carcinoma with high expression of PD-L1, c-MET, and AXL.CEN case reports · 2025Article
- Clear cell renal cell carcinoma with collecting duct carcinoma transformation: a case report and review of the literature.BMC urology · 2025Review
- Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan.BMC cancer · 2025Article
- Rare Case of Collecting Duct Carcinoma With Complete Response to Nivolumab.Case reports in oncological medicine · 2025Article
- Establishment of a nomogram to predict the overall survival of patients with collecting duct renal cell carcinoma.Discover oncology · 2024Article
- Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.Journal of pharmaceutical health care and sciences · 2024Article
- Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib.IJU case reports · 2024Article
- Article
- A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney.Asian journal of urology · 2023Article
- Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases.IJU case reports · 2022Article
- Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.Journal of medical case reports · 2022Article
- Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to ImproveWorld journal of oncology · 2021Review
- Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma.BioMed research international · 2021Article
- Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review.Frontiers in oncology · 2021Article
- Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.Case reports in urology · 2021Article
- Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collecting duct carcinoma (CDC) of the kidney is a rare subtype of renal cell carcinoma (RCC) arising from the distal collecting tubules, characterized by an aggressive phenotype, unfavorable response to several types of systemic agent and a poor prognosis. Recently, treatments with immune checkpoint inhibitors have been widely performed for patients with metastatic RCC; however, no data are available regarding the impact of first-line combination therapy with nivolumab and ipilimumab on metastatic CDC. Here, we report a CDC patient with multiple lymph node metastases who underwent cytoreductive open nephrectomy and subsequently, received nivolumab and ipilimumab therapy. Following four courses of this combined therapy, all nodal metastases had shrunk to < 1 cm in diameter, and thus this patient was judged to show a complete response (CR). To our knowledge, this is the first reported case of a patient with metastatic CDC achieving a CR to combined treatment with nivolumab and ipilimumab, which could be a promising first-line therapy against metastatic CDC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.